Jasper Therapeutics January 2023 Investor Presentation c-Kit

Jasper Therapeutics presents its clinical validation strategy for Briquilimab, an anti c-Kit antibody candidate in development for acute and chronic mast and stem cell diseases. The company has demonstrated clinical validation across five transplant indications (AML, MDS, SCID, SCD, FA) and is expanding into chronic disease areas including chronic spontaneous urticaria with multiple near-term data catalysts expected through 2024.